



## Xencor to Participate at Upcoming Investor Conferences

November 10, 2025

PASADENA, Calif.--(BUSINESS WIRE)--Nov. 10, 2025-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate at multiple upcoming investor conferences:

- **TD Cowen Immunology and Inflammation Virtual Summit**

Date: Wednesday, November 12, 2025

Presentation Time: 3:00 p.m. ET / 12:00 p.m. PT

- **Piper Sandler 37th Annual Healthcare Conference**

Date: Tuesday, December 2, 2025

Presentation Time: 2:00 p.m. ET / 11:00 a.m. PT

Live webcasts of the presentations will be available under "Events & Presentations" in the Investors section of the Company's website located at [www.xencor.com](http://www.xencor.com). Replays of the events will be available on the Xencor website for at least 30 days following the presentations.

### About Xencor

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and multiple XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein's structure that result in new mechanisms of therapeutic action. For more information, please visit [www.xencor.com](http://www.xencor.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20251110946225/en/): <https://www.businesswire.com/news/home/20251110946225/en/>

Charles Liles

[cliles@xencor.com](mailto:cliles@xencor.com)

(626) 737-8118

Source: Xencor, Inc.